Telmisartan/hydrochlorothiazide

Last updated

Telmisartan/hydrochlorothiazide
Combination of
Telmisartan Angiotensin II receptor antagonist
Hydrochlorothiazide Thiazide diuretic
Clinical data
Trade names Micardis Plus, Micardis HCT, others
AHFS/Drugs.com Professional Drug Facts
License data
Pregnancy
category
  • AU:D
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
Formula C40H38ClN7O6S2
Molar mass 812.36 g·mol−1
3D model (JSmol)
  • CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C.C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl
  • InChI=1S/C33H30N4O2.C7H8ClN3O4S2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39;8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39);1-2,10-11H,3H2,(H2,9,12,13)
  • Key:OZCVMXDGSSXWFT-UHFFFAOYSA-N
   (verify)

Telmisartan/hydrochlorothiazide, sold under the brand name Micardis HCT among others, is a fixed-dose combination medication used to treat high blood pressure. [3] It is a combination of telmisartan an angiotensin II receptor antagonist with hydrochlorothiazide a diuretic. [3] It may be used if telmisartan by itself is not sufficient. [6] It is taken by mouth. [6]

Common side effects include dizziness, upper respiratory tract infections, nausea, diarrhea, and tiredness. [3] Severe side effects may include kidney problems, electrolyte problems, and allergic reactions. [3] Use during pregnancy may harm the baby. [3] Telmisartan works by blocking the effects of angiotensin II while hydrochlorothiazide works by decreasing the kidneys' ability to retain water. [3]

The combination was approved for medical use in the United States in November 2000, [7] [8] and in the European Union in April 2002. [4] [5] The combination is on the World Health Organization's List of Essential Medicines. [9] It is available as a generic medication. [6]

References

  1. ↑ "Micardis Plus Product information". Health Canada . 16 August 2001. Retrieved 17 February 2025.
  2. ↑ "MicardisPlus 40 mg/12.5 mg Tablets - Summary of Product Characteristics (SmPC)". (emc). 28 May 2020. Retrieved 23 November 2020.
  3. 1 2 3 4 5 6 7 "Micardis HCT- telmisartan and hydrochlorothiazide tablet". DailyMed. 27 August 2020. Retrieved 4 October 2020.
  4. 1 2 "MicardisPlus EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 4 October 2020.
  5. 1 2 "PritorPlus EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 4 October 2020.
  6. 1 2 3 British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 178. ISBN   9780857113382.
  7. ↑ "Drug Approval Package: Micardis HCT (telmisartan/hydrochlorothiazide) NDA #021162". U.S. Food and Drug Administration (FDA). 11 March 2004. Retrieved 4 October 2020.
  8. ↑ "Hydrochlorothiazide and telmisartan Uses, Side Effects & Warnings". Drugs.com. Retrieved 29 October 2019.
  9. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.